Be part of the knowledge.™

Oncology and Hematology

80

LikeLikedUnlike

Episodes 136-150 of 231

Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
MinuteCE®
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
- Elizabeth R. Plimack, MD, MS, FASCO
  Peer
- Lillibeth Velasco, MSN, RN
  Peer
0.50 credits 3 episodes
Reviewing the Latest Bladder Cancer Practice Guidelines
MinuteCE®
Reviewing the Latest Bladder Cancer Practice Guidelines
- Elizabeth R. Plimack, MD, MS, FASCO
  Peer
0.50 program credits
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
MinuteCE®
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
- Elizabeth R. Plimack, MD, MS, FASCO
  Peer
0.50 program credits
Patient Perspectives on Bladder Cancer
MinuteCE®
Patient Perspectives on Bladder Cancer
- Elizabeth R. Plimack, MD, MS, FASCO
  Peer
- Lillibeth Velasco, MSN, RN
  Peer
0.50 program credits
advertisement
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
CME/CE
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer
0.50 credits
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
CME/CE
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
- Heather McArthur, MD
  Peer
- Margaret Gatti-Mays, MD, MPH
  Peer
0.25 credits
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
Molecular Profiling for HER2+ Advanced Solid Tumors
CME/CE
Molecular Profiling for HER2+ Advanced Solid Tumors
- Eric Van Cutsem, MD, PhD
  Peer
- David SP Tan, MBBS, PhD, PRCP
  Peer
- James Chih-Hsin Yang, MD, PhD
  Peer
- Kathleen Moore, MD, MS, FASCO
  Peer
1.00 credits
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
- Jeffrey V. Matous, MD
  Peer
- Donna Catamero, NP
  Peer
0.25 credits
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CE
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
- Jorge E. Cortes, MD
  Peer
0.25 credits
advertisement
MinuteCE®
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 credits 2 episodes
Diagnosis and Management of Metastatic PDAC
MinuteCE®
Diagnosis and Management of Metastatic PDAC
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 program credits
Chemotherapy Strategies for Metastatic PDAC
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended